What Is Glucosamine?

Glucosamine is a natural compound made in the body from glucose (blood sugar) and a nitrogen-containing amine molecule. In the body, glucosamine stimulates the manufacture of glycosaminoglycans (GAGs), structural support molecules in cartilage, tendons, and ligaments.

Is Glucosamine Anti-inflammatory?

In groundbreaking research conducted over fifty years ago at the World Health Organization (WHO), it was found that as people age, they lose the ability to manufacture sufficient levels of glucosamine. 

Without adequate glucosamine, cartilage loses its gel-like nature and ability to act as a shock absorber. Glycosaminoglycans (GAGs) serve as the structural scaffolding of cartilage and are critical to maintaining the high water content of cartilage and other joint components. Without sufficient glucosamine, joints start to degenerate (break down). Glucosamine also exerts some action on inflammatory processes.

After discovering glucosamine's link to joint health, intensive scientific research has shown a rationale and role for glucosamine supplementation in supporting joint health. Glucosamine is recommended as a "first-line" approach to joint health issues by medical organizations in many parts of the world.

What Is Glucosamine Good For?

Joint Health Benefits

Glucosamine sulfate is the best form of glucosamine and the key dietary supplement to promote joint health. Numerous double-blind studies in humans have shown GS to produce significant improvements in pain, indexes of joint function, and blood markers of cartilage health. Typically, these benefits are seen after 2 to 4 weeks of use, but there is some evidence that the longer GS is used, the greater the joint health benefits.

The two longest placebo-controlled trials were three years in duration. The results from these studies showed, quite convincingly, that GS slowed down the progression of cartilage breakdown associated with aging or mechanical stress on joints, as noted by improvements in X-rays and clinical evaluation. Results also showed a significantly reduced number of total joint replacements in those who took GS in these studies even as much as 5 years after they stopped taking GS.

Injury Prevention and Recovery

GS may be a preventive measure against cartilage degeneration, especially in athletes subjected to joint strain, such as runners or those involved in soccer, football, basketball, or other weight-bearing sports. GS may also help aid in recovering from minor acute joint sprains and strains. One double-blind study showed the the protective action of GS on cartilage in soccer players taking 1,500 or 3,000 mg per day for 3 months by demonstrating an increase in a blood marker for cartilage synthesis and a reduced ratio showing cartilage breakdown.

Food Sources of Glucosamine

There are no food sources of glucosamine. It is only available as a dietary supplement. Most commercially available sources of glucosamine are derived from chitin – the exoskeleton of shrimp, lobsters, and crabs. A vegan form produced from a corn-based microbial fermentation is also available.

Forms of Glucosamine: Which Is Best?

Glucosamine Sulfate (GS)

Glucosamine sulfate (GS) has been extensively researched, with over 300 scientific investigations and 30 double-blind studies highlighting its effectiveness. It is the preferred form of glucosamine and has been widely embraced by millions worldwide. 

Registered as an aid in joint health in over 70 countries, GS has demonstrated remarkable qualities.

Human studies focusing on the absorption and distribution of GS reveal an impressive absorption rate of up to 98%. Once absorbed, it primarily targets joint tissues for the production of cartilage, ligaments, and tendons. This underscores its crucial role in supporting joint health.

Glucosamine Hydrochloride (GHCL)

Because one of the primary effects of glucosamine sulfate (GS) is to promote the manufacture of glycosaminoglycans (GAGs), a lack of sulfur may mean less GAG synthesis when glucosamine hydrochloride (GHCL) is used. 

Therefore, it is unlikely that GHCL alone will show the same excellent clinical results achieved with GS because it lacks this critical element.

Results from double-blind studies have shown that GHCL is no more effective than a placebo in promoting joint health. One double-blind, placebo-controlled human study examined the effects of GHCL on knee health in human subjects. Subjects received either 500 mg of GHCL or a placebo three times daily for 10 weeks. Results showed the difference between the two groups was not statistically significant.

In one of the most extensive studies with GHCL, 1,583 patients with knee pain and poor joint function were randomized to receive each day for 24 weeks either 1,500 mg of GHCL, 1,200 mg of chondroitin sulfate, both GHCL and chondroitin sulfate (same dosages as the single arms), 200 mg of celecoxib, or placebo. Results showed that in patients with moderate-to-severe pain at the beginning of the study, the response rate was significantly higher in subjects who took both GHCL and chondroitin sulfate compared to the placebo (79.2% vs. 54.3%). However, there was no benefit over placebo in the groups getting GHCL or chondroitin sulfate.

N-acetylglucosamine (NAG)

N-acetylglucosamine (NAG) differs from glucosamine sulfate (GS) in that instead of an attached sulfur molecule, it has a portion of an acetic acid molecule. As a result, GS and NAG are handled differently by the body. While glucosamine is easily absorbed, NAG is not. The absorption of NAG by humans is poor for several reasons:

  • NAG is quickly digested by intestinal bacteria.
  • NAG binds with dietary lectins in the gut, resulting in a lectin-NAG complex excreted in the feces.
  • A large percentage of NAG is metabolized by intestinal cells.

In addition to the question of absorption, joint tissue cannot use NAG as well as it does glucosamine. These absorption and utilization issues indicate NAG is highly unlikely to possess the same benefits to joint health as GS. Companies selling NAG claim that NAG is a better form of glucosamine for joint health, but scientific data do not support these claims.

Dosage

The standard dosage for GS is 1500 mg/day, and taking it as a single dosage may produce better results. Also, athletes or people subjecting their joints to more significant wear and tear may need to increase the dosage to 3,000 mg to support cartilage health.

Side Effects and Safety

Glucosamine Sulfate has an excellent safety record. It has been concluded that side effects are no different from placebo, are rare, and are generally limited to mild gastrointestinal irritation.

Glucosamine and Chondroitin 

Glucosamine is often discussed with chondroitin sulfate (CS). However, based on the extensive clinical evidence, only glucosamine sulfate (GS) has consistently proven its clinical effectiveness when used as a standalone agent. Numerous studies have shown that combining Glucosamine Hydrochloride (GHCL) and chondroitin sulfate is effective, and GS alone offers the most robust clinical benefits.

Furthermore, research indicates that combining GS with chondroitin sulfate does not provide significantly greater benefits than GS alone. However, when GS or GS+CS is combined with methylsulfonylmethane (MSM), it may offer additional beneficial effects. Similarly, using MSM with GHCL can enhance the benefits of GHCL by providing essential sulfur.

Sulfur plays a critical role in the therapeutic effects of GS, and substituting it is likely to reduce the efficacy of supplemental glucosamine. This nutrient is vital for joint tissue, as it stabilizes the connective tissue matrix of cartilage, tendons, and ligaments. Additionally, sulfur helps protect against cartilage degeneration. Thus, maintaining adequate sulfur content in glycosaminoglycans (GAGs) is crucial to prevent cartilage deterioration.

Takeaway

Overall, the extensive research on glucosamine sulfate underscores its importance in supporting joint health and its significant role in promoting overall well-being.

References:

  1. Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther. 2012 Jan 30;14(1):201.
  2. Herrero-Beaumont G, Largo R. Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation? Ann Rheum Dis. 2020 Oct;79(10):1261-1263.
  3. Conrozier T, Lohse T. Glucosamine as a Treatment for Osteoarthritis: What If It's True? Front Pharmacol. 2022 Mar 17;13:820971. 
  4. Knapik JJ, Pope R, Hoedebecke SS, et al. Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis. J Spec Oper Med. 2018 Winter;18(4):139-147.
  5. Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337-350.
  6. Knapik JJ, Pope R, Hoedebecke SS, Schram B, Orr R, Lieberman HR. Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis. J Spec Oper Med. 2018 Winter;18(4):139-147.
  7. Setnikar I, Palumbo R, Canali S, et al. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993; 43:1109–1113.
  8. Zhu X, Sang L, Wu D, et al. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018 Jul 6;13(1):170. 
  9. Meng Z, Liu J, Zhou N. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. Arch Orthop Trauma Surg. 2023 Jan;143(1):409-421.
  10. Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018 Jun 11. doi: 10.1007/s00296-018-4077-2.
  11. Lubis AMT, Siagian C, Wonggokusuma E, Marsetyo AF, Setyohadi B. Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial. Acta Med Indones. 2017 Apr;49(2):105-111.
  12. Nunes RM, Girão VCC, Cunha PLR, et al. Decreased Sulfate Content and Zeta Potential Distinguish Glycosaminoglycans of the Extracellular Matrix of Osteoarthritis Cartilage. Front Med (Lausanne). 2021 Apr 29;8:612370.
  13. Houpt J.B, McMillan R, Wein C, et al. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423–2430.
  14. Sawitzke A.D, Shi H, Finco M.F, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008;58:3183–3191.
  15. Sawitzke A.D, Shi H, Finco M.F, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010;69:1459–1464.
  16. Capps JC, Shetlar MR, Bradford RH. Hexosamine metabolism. I. The absorption and metabolism, in vivo, of orally administered D-glucosamine and N-acetyl-D-glucosamine in the rat. Biochim Biophys Acta 1966;127194–204.
  17. Tesoriere G, Dones F, Magistro; et al. Intestinal absorption of glucosamine and N-acetylglucosamine. Experientia 1972;28 770–771.
  18. Bruyere O, Pavelka K, Rovati LC, et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004;11:138–143.
  19. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251–256.
  20. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113–2123.
  21. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008;16;254–260.
  22. Bruyere O, Honore A, Ethgen O, et al. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage 2003;1:1–5.
  23. Nagaoka I, Tsuruta A, Yoshimura M. Chondroprotective action of glucosamine, a chitosan monomer, on the joint health of athletes. Int J Biol Macromol. 2019 Jul 1;132:795-800.
  24. Yoshimura M, Sakamoto K, Tsuruta A, et al. Evaluation of the effect of glucosamine administration on biomarkers for cartilage and bone metabolism in soccer players. Int J Mol Med 2009;24:487–494.